BlueRun Ventures-backed Zenitar closes nearly RMB 600 million Series C round | BlueRun Family
Build a closed-loop, iterative system spanning "target identification — molecular design — efficacy validation"
Zenitar (成都赜灵生物医药科技股份有限公司) has announced the completion of a nearly RMB 600 million Series C financing round. The round was co-led by True Light Capital, a wholly-owned subsidiary of Temasek, and Qiming Venture Partners, with participation from BlueRun Ventures, Tencent, C&D Emerging Investment, and Shanghai Science and Technology Innovation Fund. Existing shareholders 5Y Capital, Huajin Capital, Guosheng Capital, and Sichuan Science and Technology Innovation Investment Group continued to increase their stakes.
Zenitar integrates three platforms — structural biology, AI-powered drug discovery and design, and clinically relevant disease model screening — to build a "three-in-one" collaborative R&D engine. This creates a closed-loop iterative system spanning from target identification to molecular design to efficacy validation, enabling the development of a pipeline of highly differentiated small-molecule drugs. Its lead programs have demonstrated best-in-class (BIC) potential through head-to-head clinical trials against global standard-of-care (SOC) therapies. We look forward to new breakthroughs in domestic and international clinical trials for Zenitar's two hematology/oncology drug candidates currently in Phase III registrational studies.
Proceeds from this round will primarily support global clinical development, pipeline expansion, and technology platform upgrades. Specifically, this includes: First, global clinical development. Accelerating the advancement of two globally competitive hematology/oncology candidates in Phase III registrational studies while expanding clinical development into additional indications, and simultaneously initiating overseas clinical trials for multiple immunology/inflammation and central nervous system candidates to build international market presence; Second, pipeline expansion. Advancing both indication expansion for existing assets and parallel development of differentiated molecules against new targets to continuously enrich and upgrade the innovative drug pipeline; Third, technology platform upgrades. Continuously strengthening the synergy across its three core technology platforms — ZeniFold, with deep structural biology resolution capabilities; ZeniMind, for AI-driven drug discovery and design; and ZeniScreen, for clinically relevant disease model screening — to systematically enhance end-to-end drug development capabilities.
Zenitar Clinical and Preclinical Product Portfolio (Partial)
Founded in 2019, Zenitar is a late-clinical-stage biotechnology company. By integrating structural biology, artificial intelligence, and clinical-grade disease models, the company has built an integrated core technology platform for novel drug R&D, efficiently constructing a diversified pipeline with global competitiveness and significant differentiation advantages. The company is dedicated to developing highly differentiated small-molecule therapies with "first-in-class" or "best-in-class" potential. Zenitar focuses on hematologic diseases, oncology, central nervous system (CNS), and inflammation/immunology (I&I), aiming to establish innovative treatment standards or significantly improve upon existing efficacy for diseases with major unmet clinical needs.
Zenitar integrates ZeniFold (structural biology platform), ZeniMind (AI drug discovery and design platform), and ZeniScreen (clinically relevant disease model screening platform) to build a "three-in-one" collaborative R&D engine, forming a closed-loop iterative system from target identification to molecular design to efficacy validation. ZeniFold leverages high-precision protein structure resolution to accurately locate drug-binding sites and guide molecular scaffold design; ZeniMind employs proprietary AI algorithms to enable intelligent molecular generation and multi-objective parameter optimization; ZeniScreen utilizes clinically relevant disease models to systematically complete efficacy validation and clinical translation potential assessment. Through this "structure resolution — AI design — disease model validation — structure back-validation" closed-loop process, Zenitar achieves continuous mutual validation and iterative optimization of computational and experimental data, significantly improving lead compound discovery efficiency and candidate drug quality, and successfully supporting the formation and advancement of multiple small-molecule programs in the company's pipeline.
Zenitar Novel Drug R&D Platform Synergy Mechanism
Committed to an innovation-driven development strategy, Zenitar will continue to deepen its global footprint, accelerate the release of technical potential in core platforms such as structural biology and AI drug design, systematically enhance the competitiveness and clinical value of its innovative drugs in international markets, drive more globally first-in-class drug candidates into clinical stages, and provide innovative solutions for unmet clinical needs.
